 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...1112131415161718192021...235236» |
- ||| Vectibix (panitumumab) / Amgen
Trial completion, Trial completion date, Trial primary completion date: Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer (clinicaltrials.gov) - Jul 16, 2024
P2, N=75, Completed, Sponsor: Memorial Sloan Kettering Cancer Center
Active, not recruiting --> Completed | Trial completion date: Mar 2025 --> Jul 2024 | Trial primary completion date: Mar 2025 --> Jul 2024
- || Rytelo (imetelstat) / Geron
Enrollment open: A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy (clinicaltrials.gov) - Jul 16, 2024
P1, N=36, Recruiting, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed | Trial completion date: Mar 2025 --> Jul 2024 | Trial primary completion date: Mar 2025 --> Jul 2024 Not yet recruiting --> Recruiting
- Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
A randomized phase I/II study of second line treatment with liposomal irinotecan and S-1 versus liposomal irinotecan and 5-fluorouracil in patients with metastatic pancreatic cancer following gemcitabine-based chemotherapy (Bilbao Auditorium - Hall 2) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1700;
P2
This study aimed to compare second-line treatment with S-1 and liposomal irinotecan (nal-IRI) to 5-fluorouracil/ leucovorin (5-FU/LV) and nal-IRI in metastatic pancreatic cancer patients...Conclusions Second-line treatment with nal-IRI plus S-1 did not improve PFS compared with nal-IRI plus 5-FU/LV in patients with metastatic pancreatic cancer following first-line gemcitabine-based chemotherapy. However, OS tended to improve in patients treated with nal-IRI plus 5-FU/LV.
- Avastin (bevacizumab) / Roche
SOLARIS (Alliance A021703): A multicenter double-blind phase III randomized clinical trial (RCT) of vitamin D (VitD) combined with standard chemotherapy plus bevacizumab (bev) in patients (pts) with previously untreated metastatic colorectal cancer (mCRC) (Madrid Auditorium - Hall 2) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1576;
P3
Pts received mFOLFOX6 or FOLFIRI + bev with 1:1 randomization to high-dose VitD3 (8,000 IU/d x 14d then 4,000 IU/d) vs standard-dose (400 IU/d)...The most common grade ?3 toxicities were not different between arms, including neutropenia/leukopenia, hypertension, peripheral neuropathy, and diarrhea. Conclusions Addition of high-dose VitD3 to standard treatment did not improve PFS vs standard-dose VitD3 in pts with mCRC, although a potential benefit was seen in pts with left-sided mCRC.
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Modified FOLFOX plus/minus nivolumab and ipilimumab vs FLOT plus nivolumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Final results of the IKF-AIO-Moonlight trial (Madrid Auditorium - Hall 2) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1489;
P2
b) The use of sequential chemo followed by IO monotherapy is insufficient. c) FLOT and nivolumab is feasible and seems to be associated with improved efficacy.
- 5-fluorouracil / Generic mfg.
A randomized phase III trial of perioperative chemotherapy (periop CT) with or without preoperative chemoradiotherapy (preop CRT) for resectable gastric cancer (AGITG TOPGEAR): Final results from an intergroup trial of AGITG, TROG, EORTC and CCTG (Madrid Auditorium - Hall 2) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1488;
P2/3
Preop CRT was not associated with increased perioperative treatment toxicity or a higher rate of surgical complications. Conclusions Despite improving pathological outcomes, the addition of preop CRT to periop CT does not improve overall survival compared to periop CT alone in patients with resectable gastric and gastro-esophageal junction adenocarcinoma.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Preoperative modified FOLFIRINOX (mFOLFIRINOX) with or without chemoradiation (CRT) in borderline resectable pancreatic cancer (BRPC): Results from the randomized phase II trial PANDAS/PRODIGE 44 (Sevilla Auditorium - Hall 2) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1437;
P2
Those who had tumour controlled at restaging were randomized between two additional cycles of mFOLFIRINOX (arm A) alone or followed by a CRT (50.4 Gy in 28 fractions with capecitabine 825mg/m2 BID 5 days a week) prior to surgery. Patients without disease progression then underwent a pancreatectomy and adjuvant chemotherapy for 3 months (gemcitabine or 5-FU/folinic acid before 6/2008, mFOLFIRINOX thereafter)...R0 resection was achieved in 20/37 pts (54.1%) in arm A and 18/31 pts (58.1%) in arm B. ypCR was observed in 3 pts (8.1%) in arm A and 9 (29%) in arm B. The median OS was 32.8 months (95%CI: 22.7
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
New trial: A prospective,randomized controlled,multicenter clinical study of Buzhong Tiaogan Granules combined with chemotherapy in the treatment of liver metastasis in coloretal cancer (EUDRACT) - Jul 15, 2024
P=N/A, N=210, Not yet recruiting, Sponsor: Shanxi Province Hospital of Traditional Chinese Medicine; Shanxi Province Hospital of Traditional Chinese Medicine
- | leucovorin calcium / Generic mfg.
New trial: Clinical observation on the treatment of asthenospermia with "Zhibian(BL54) to Shuidao(ST28)" needling manipulation (EUDRACT) - Jul 15, 2024
P=N/A, N=72, Not yet recruiting, Sponsor: the affilinated Acunpuncture and Tuina hospital of Shanxi University of Chinese Medicine; Shanxi Provincial Acupuncture Hospital
- | Erbitux (cetuximab) / Eli Lilly
New trial: Prevention of pruritus in patients with advanced colorectal cancer treated with mFOLFOX6 in combination with cetuximab as first-line therapy: A multi-center, prospective, observational cohort study (EUDRACT) - Jul 15, 2024
P=N/A, N=1400, Not yet recruiting, Sponsor: The First Affiliated Hospital, Zhejiang University School of Medicine; The First Affiliated Hospital, Zhejiang University School of Medicine
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P3 trial: Portal vein ligation combined with hepatic arterial infusion chemotherapy, Apatinib, carrilizumab versus ALPPS postoperative combined with Apatinib and carrilizumab in the treatment of hepatocellular carcinoma with Inadequate future-liver-remnant: a multicenter, phase III, randomized controlled clinical trial (EUDRACT) - Jul 15, 2024
P3, N=100, Recruiting, Sponsor: The First Affiliated Hospital of Guangxi Medical University; The First Affiliated Hospital of Guangxi Medical University
- | TheraCIM (nimotuzumab) / Daiichi Sankyo, Oncoscience, Biocon, Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
New P2 trial: A prospective, single arm study of Nimotuzumab combined with NALIRIFOX in the treatment of locally advanced pancreatic cancer (EUDRACT) - Jul 15, 2024
P2, N=31, Not yet recruiting, Sponsor: Peking Union Medical College Hospital; Peking Union Medical College Hospital
- | Avastin (bevacizumab) / Roche
New P2 trial, Metastases: A randomized, controlled, multicenter, phase II clinical trial of the combination of Fosapitam with chemotherapy and bevacizumab in the second-line treatment of advanced colorectal cancer (EUDRACT) - Jul 15, 2024
P2, N=82, Not yet recruiting, Sponsor: The 903rd Hospital of the Joint Logistics Support Force of the People's Liberation Army of China; The 903rd Hospital of the Joint Logistics Support Fo
- | Keytruda (pembrolizumab) / Merck (MSD), Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
New P1 trial, IO biomarker, Metastases: Clinical Study of the Combination of Pembrolizumab and NALIRIFOX Compared to NALIRIFOX Neoadjuvant Therapy in Locally Advanced Pancreatic Cancer (EUDRACT) - Jul 15, 2024
P1, N=94, Not yet recruiting, Sponsor: Peking Union Medical College Hospital; Peking Union Medical College Hospital
- | 5-fluorouracil / Generic mfg.
Journal, Metastases: BRAF V600E-mutated Colorectal Neuroendocrine Carcinoma Effectively Treated with a Chemotherapy Protocol for BRAF-mutated Metastatic Colorectal Cancer: A Case Report. (Pubmed Central) - Jul 15, 2024
Despite discontinuing binimetinib due to myalgia, she had a long-term response with a progression-free survival of 14 months and an overall survival of more than 27 months. A chemotherapy protocol for BRAF-mutated metastatic colorectal cancer may be a treatment option for BRAF V600E-mutated colorectal NEC.
- || Review, Journal: Natural products as inhibitors against pancreatic cancer cell proliferation and invasion: possible mechanisms. (Pubmed Central) - Jul 15, 2024
And drug resistance emerges during the application of the most widely used chemotherapeutic regimens such as modified FOLFIRINOX regimen, gemcitabine monotherapy or 5-Fluorouracil combination therapy, which further reduces the therapeutic efficacy...Meanwhile, natural products have also hindered the progress of their basic and clinical research due to the complexity of their composition and the limitation of biological extraction technology. Further exploration of the specific molecular mechanisms of natural products to inhibit the proliferation and invasion of pancreatic cancer cells, optimization of purification and preparation techniques, and enrichment of basic and clinical trials to verify their efficacy and safety may be the future direction of natural products in the field of anti-pancreatic cancer research.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Journal: Identification of a Novel Protein Phosphatase 2A Activator, PPA24, as a Potential Therapeutic for FOLFOX-Resistant Colorectal Cancer. (Pubmed Central) - Jul 15, 2024
Furthermore, a PPA24-encapsulated nanoformulation significantly inhibited the growth of CRC xenografts without systemic toxicities. Together, these results signify the potential of PPA24 as a novel PP2A activator and a prospective therapeutic for CRC and FOLFOX-resistant CRC.
- | Avastin (bevacizumab) / Roche, Ariely (adebrelimab) / Jiangsu Hengrui Pharma
Enrollment open, Combination therapy: OBU-HCC-II-001: Evaluation of Effectiveness and Safety of HAIC in Combination With Adebrelimab and Bevacizumab for Potentially Resectable Hepatocellular Carcinoma (clinicaltrials.gov) - Jul 15, 2024
P2, N=40, Recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
Together, these results signify the potential of PPA24 as a novel PP2A activator and a prospective therapeutic for CRC and FOLFOX-resistant CRC. Not yet recruiting --> Recruiting
- | lestaurtinib (CEP-701) / Teva, Kyowa Kirin
Trial completion: AALL0631: Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jul 15, 2024
P3, N=218, Completed, Sponsor: Children's Oncology Group
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
New P3 trial: Liposomal Irinotecan and 5-FU as Second-line Therapy for Patients With ESCC (clinicaltrials.gov) - Jul 15, 2024
P3, N=360, Not yet recruiting, Sponsor: Rui-hua Xu, MD, PhD
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
New P3 trial: IRIMAD: Adjuvant FOLFIRI Based-chemotherapy After Resection of CLM Responding to Preoperative FOLFIRI (clinicaltrials.gov) - Jul 14, 2024
P3, N=254, Not yet recruiting, Sponsor: Assistance Publique - H
- | 5-fluorouracil / Generic mfg.
New P2 trial, Metastases: INOVA-2024-27: Study of 5-fluorouracil (5-FU) in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Jul 14, 2024
P2, N=10, Not yet recruiting, Sponsor: Inova Health Care Services
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Review, Journal: Consensus Guidelines of Irreversible Electroporation for Pancreatic Tumors: Protocol Standardization Using the Modified Delphi Technique. (Pubmed Central) - Jul 12, 2024
This article provides expert recommendations regarding patient selection, procedure, and follow-up for IRE treatment in pancreatic malignancies through a modified Delphi consensus study. Future studies should define the maximum tumor diameter, response evaluation criteria, and the optimal number of preoperative FOLFIRINOX cycles.
- ||||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion: CheckMate 649: Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer (clinicaltrials.gov) - Jul 11, 2024
P3, N=2031, Completed, Sponsor: Bristol-Myers Squibb
Future studies should define the maximum tumor diameter, response evaluation criteria, and the optimal number of preoperative FOLFIRINOX cycles. Active, not recruiting --> Completed
- ||| petosemtamab (MCLA-158) / Merus
Enrollment change, Trial completion date, Trial primary completion date, Metastases: MCLA-158-CL01: A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jul 11, 2024
P1/2, N=567, Recruiting, Sponsor: Merus N.V.
Active, not recruiting --> Completed N=360 --> 567 | Trial completion date: Jun 2025 --> Nov 2027 | Trial primary completion date: Jun 2024 --> Nov 2025
- | Lonsurf (trifluridine/tipiracil) / Otsuka
Journal, Metastases: Long-Term Survival in a Patient with Metastatic Colorectal Cancer Treated with Trifluridine/Tipiracil as Late-Line Chemotherapy: A Case Report. (Pubmed Central) - Jul 11, 2024
The woman who was 52 years old at diagnosis of adenocarcinoma of the right colon (T3/N0/M1) with metastases to the lung, liver, ovary, and other soft tissues received first-line fluoropyrimidine-based chemotherapy (FOLFOX/FOLFIRI plus bevacizumab) intermittently for approximately 8.5 years with generally stable disease, and second-line FOLFIRI plus radiotherapy...Neutropenia was successfully managed with FTD/TPI dose delays or reductions. This heavily pre-treated patient with mCRC demonstrated impressive long-term survival and maintenance of good quality of life with FTD/TPI treatment.
- | irinotecan liposomal / CSPC Pharma
Enrollment change, Trial termination, Metastases: Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer (clinicaltrials.gov) - Jul 11, 2024
P2, N=17, Terminated, Sponsor: CSPC Ouyi Pharmaceutical Co., Ltd.
N=66 --> 17 | Not yet recruiting --> Terminated; Internal strategy change. Not related to safety concerns.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Journal: Important Radiologic and Clinical Factors for Predicting Overall Survival in Pancreatic Adenocarcinoma Patients Who Underwent FOLFIRINOX. (Pubmed Central) - Jul 10, 2024
Not related to safety concerns. Both clinical and CT findings were useful for predicting OS after FOLFIRINOX in PAC.
- || Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Clinical data, Retrospective data, Journal, HEOR, Real-world evidence, Real-world, Metastases: Clinical outcomes of liposomal irinotecan in patients with advanced pancreatic cancer previously treated with conventional irinotecan: A meta-analysis of real-world evidence. (Pubmed Central) - Jul 10, 2024
Prior IRI exposure does not affect the survival outcomes of nal-IRI regimens in patients who have advanced PDAC. The selection of later lines of chemotherapy regimens should be based on the differential safety profile, patient status, the cost of treatment, and health-related quality of life.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical data, Journal, Metastases: Effect of cetuximab plus FOLFOX4 regimen on clinical outcomes in advanced gastric carcinoma patients receiving evidence-based care. (Pubmed Central) - Jul 10, 2024
The CET + FOLFOX4 regimen is highly effective as first-line treatment for aGC patients receiving EBC. It facilitates the suppression of STMs, ameliorates the serum inflammatory microenvironment, and enhances QOL, without increased adverse drug effects.
- || NP137 / NETRIS Pharma
Trial initiation date: Study of Perioperative NP137 and FOLFIRINOX in Resectable Pancreatic Cancer (clinicaltrials.gov) - Jul 9, 2024
P1, N=25, Not yet recruiting, Sponsor: Nabeel Badri
It facilitates the suppression of STMs, ameliorates the serum inflammatory microenvironment, and enhances QOL, without increased adverse drug effects. Initiation date: Jul 2024 --> Jan 2025
- ||||| Braftovi (encorafenib) / Pfizer
Enrollment closed: BREAKWATER: A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer (clinicaltrials.gov) - Jul 9, 2024
P3, N=816, Active, not recruiting, Sponsor: Pfizer
Initiation date: Jul 2024 --> Jan 2025 Recruiting --> Active, not recruiting
- | Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
New trial, Metastases: NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus AG Combined With PD-1 Sequential Radiotherapy as First-line Treatment of Locally Advanced Pancreatic Cancer (clinicaltrials.gov) - Jul 9, 2024
P=N/A, N=40, Recruiting, Sponsor: Du Juan
- |||| SSGJ-707 / 3SBio
New P2 trial, Metastases: A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients (clinicaltrials.gov) - Jul 9, 2024
P2, N=120, Not yet recruiting, Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- | leucovorin calcium / Generic mfg.
Journal: Intratumoral NKT cell accumulation promotes antitumor immunity in pancreatic cancer. (Pubmed Central) - Jul 9, 2024
To evaluate the therapeutic potential of these observations, we find that administration of folinic acid to mice bearing PDA increases NKT cells in the TME and improves their response to anti-PD-1 antibody treatment. In conclusion, NKT cells have an essential role in the immune response to mouse PDA and are potential targets for immunotherapy.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P3 trial: Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT (clinicaltrials.gov) - Jul 9, 2024
P3, N=178, Not yet recruiting, Sponsor: Second Affiliated Hospital of Guangzhou Medical University
- | Hetronifly (serplulimab) / Fosun Pharma
New P2 trial: ASTRUM-IUmCRC: First-Line Treatment Induced With mFOLFOX6 and HLX04 Regimen, Following Combined With Serplulimab in MSS Initially Unresectable Metastatic Colorectal Cancer (clinicaltrials.gov) - Jul 9, 2024
P2, N=72, Not yet recruiting, Sponsor: Sir Run Run Shaw Hospital
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Retrospective data, Journal, HEOR, Real-world evidence, Claims database, Real-world: Real-World Evidence of FOLFIRI Combined with Anti-Angiogenesis Inhibitors or Anti-EGFR Antibodies for Patients with Early Recurrence Colorectal Cancer After Adjuvant FOLFOX/CAPOX Therapy: A Japanese Claims Database Study. (Pubmed Central) - Jul 8, 2024
This is the first administrative data-based real-world evidence on treatment sequence and outcomes for patients with early recurrence CRC treated with FOLFIRI+AAs or FOLFIRI+ anti-EGFR antibodies after adjuvant FOLFOX/CAPOX therapy in Japan. Both regimens had similar TTD, but relapse timing and tumor sidedness may influence their efficacy.
- | 5-fluorouracil / Generic mfg.
Journal, CINV: NHS-Reimbursed Cannabis Flowers for Cancer Palliative Care and the Management of Chemotherapy-Induced Nausea and Vomiting: An Autobiographical Case Report. (Pubmed Central) - Jul 8, 2024
Both regimens had similar TTD, but relapse timing and tumor sidedness may influence their efficacy. He received FOLFIRI (folinic acid, fluorouracil, and irinotecan) chemotherapy
- || AMG 193 / Amgen
Enrollment change: A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (clinicaltrials.gov) - Jul 8, 2024
P1, N=188, Recruiting, Sponsor: Amgen
He received FOLFIRI (folinic acid, fluorouracil, and irinotecan) chemotherapy N=282 --> 188
- || Vectibix (panitumumab) / Amgen
Trial primary completion date: OPTIPRIME: FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation (clinicaltrials.gov) - Jul 8, 2024
P2, N=118, Active, not recruiting, Sponsor: Federation Francophone de Cancerologie Digestive
N=282 --> 188 Trial primary completion date: Apr 2024 --> Dec 2024
- | Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
Trial completion date, Metastases: PRODIGE 59 - DURIGAST: Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma (clinicaltrials.gov) - Jul 8, 2024
P2, N=107, Active, not recruiting, Sponsor: Federation Francophone de Cancerologie Digestive
Trial primary completion date: Apr 2024 --> Dec 2024 Trial completion date: Sep 2023 --> Nov 2024
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., docetaxel / Generic mfg.
Trial completion date, Trial primary completion date: GASTFOX: PHASE III RANDOMISED TRIAL to EVALUATE FOLFOX with or WITHOUT DOCETAXEL (TFOX) AS 1st LINE CHEMOTHERAPY for LOCALLY ADVANCED or METASTATIC OESOPHAGO-GASTRIC CARCINOMA (clinicaltrials.gov) - Jul 8, 2024
P3, N=507, Active, not recruiting, Sponsor: Federation Francophone de Cancerologie Digestive
Trial completion date: Sep 2023 --> Nov 2024 Trial completion date: Mar 2024 --> Dec 2025 | Trial primary completion date: Apr 2023 --> Dec 2025
- | Erbitux (cetuximab) / Eli Lilly
New P2 trial, Circulating tumor DNA: Chemotherapy Plus EGFR Monoclonal Antibody in Patients With Liver Metastases From Colorectal Cancer With ctDNA Superselective Negative Genes (clinicaltrials.gov) - Jul 8, 2024
P2, N=33, Not yet recruiting, Sponsor: Fujian Cancer Hospital
- | New P3 trial: The Sagittarius Trial (clinicaltrials.gov) - Jul 7, 2024
P3, N=700, Not yet recruiting, Sponsor: IFOM ETS - The AIRC Institute of Molecular Oncology
- | Trial completion date, Trial primary completion date, Metastases: Induction Chemotherapy for Locally Advanced Esophageal Cancer (clinicaltrials.gov) - Jul 7, 2024
P2, N=40, Active, not recruiting, Sponsor: University of Rochester
Trial completion date: Mar 2024 --> Dec 2025 | Trial primary completion date: Apr 2023 --> Dec 2025 Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Jun 2025
- || Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
P2 data, Journal: Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label, randomised, phase 2 trial. (Pubmed Central) - Jul 6, 2024
P2
The addition of nanoliposomal irinotecan to fluorouracil plus leucovorin did not improve progression-free survival or overall survival and was associated with higher toxicity compared with fluorouracil plus leucovorin. Further research is necessary to define the role of irinotecan-based combinations in second-line treatment of biliary tract cancer.
- | methotrexate / Generic mfg.
Journal: Methotrexate might become the sole treatment option for leukemia following the occurrence of Stevens-Johnson syndrome. (Pubmed Central) - Jul 6, 2024
As far as we know, the prophylactic use of IVIG to counteract SCARs in a pediatric leukemia patient represents uncharted territory. Moreover, research into the immune system dynamics within these patients and the preservation of indispensable treatments should involve allergist-immunologists as part of the multidisciplinary team attending to neoplastic conditions.
- || Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
P1 data, Journal: A phase-I study of second-line S-IROX for unresectable pancreatic cancer after gemcitabine plus nab-paclitaxel failure. (Pubmed Central) - Jul 5, 2024
Second-line S-IROX treatment was deemed acceptable. The RD was set at level-1 dose (S-1, 80
- | Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Trial completion date, Trial primary completion date, Metastases: Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer (clinicaltrials.gov) - Jul 4, 2024
P2, N=92, Active, not recruiting, Sponsor: National Health Research Institutes, Taiwan
The RD was set at level-1 dose (S-1, 80 Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024